LYN - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
MET	MET proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels	K-252a SGX-523 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol AMG-208 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Capmatinib Fostamatinib Tivantinib Brigatinib Amuvatinib	Renal cell carcinoma Cholangiocarcinoma Gastric cancer
PIK3CG	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	GPVI-mediated activation cascade Synthesis of PIPs at the plasma membrane G beta:gamma signalling through PI3Kgamma Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	Staurosporine Myricetin LY-294002 Quercetin 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE XL765 TG100-115 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE Wortmannin 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Duvelisib Fostamatinib
CASP3	caspase 3	Activation of caspases through apoptosome-mediated cleavage SMAC (DIABLO) binds to IAPs SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes Apoptotic cleavage of cellular proteins SMAC, XIAP-regulated apoptotic response Apoptosis induced DNA fragmentation Degradation of the extracellular matrix Signaling by Hippo NADE modulates death signalling Stimulation of the cell death response by PAK-2p34 Caspase-mediated cleavage of cytoskeletal proteins Apoptotic cleavage of cell adhesion proteins Caspase activation via Dependence Receptors in the absence of ligand Caspase activation via Dependence Receptors in the absence of ligand Other interleukin signaling	Pamidronic acid Acetylsalicylic acid Minocycline 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid Emricasan Incadronic acid 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE [N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide Glycyrrhizic acid
IL1B	interleukin 1 beta	Interleukin-1 processing CLEC7A/inflammasome pathway Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling Interleukin-1 signaling Purinergic signaling in leishmaniasis infection	Donepezil Minocycline VP025 Gallium nitrate Talmapimod Etiprednol dicloacetate VX-702 VX-765 Andrographolide Canakinumab Rilonacept Foreskin keratinocyte (neonatal) Binimetinib Gevokizumab Dilmapimod
ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Choriocarcinoma Pancreatic cancer Gastric cancer Bladder cancer Endometrial Cancer Ovarian cancer Cholangiocarcinoma Breast cancer Cervical cancer
JAK2	Janus kinase 2	Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Prolactin receptor signaling Prolactin receptor signaling Signaling by SCF-KIT Signaling by Leptin RMTs methylate histone arginines Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF activation RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cyclin D associated events in G1 Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-35 Signalling Signaling by Erythropoietin Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Potential therapeutics for SARS Growth hormone receptor signaling Growth hormone receptor signaling Factors involved in megakaryocyte development and platelet production	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one XL019 5-phenyl-1H-indazol-3-amine 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM Ruxolitinib Tofacitinib Baricitinib Entrectinib Fostamatinib Fedratinib Zanubrutinib Pralsetinib	Polycythemia vera
GRIA3	glutamate ionotropic receptor AMPA type subunit 3	Activation of AMPA receptors Trafficking of AMPA receptors Trafficking of GluR2-containing AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Synaptic adhesion-like molecules	Glutamic acid Butabarbital Ethanol Lithium cation Aniracetam Talampanel CX-717 Fluciclovine (18F) Lithium citrate Lithium succinate Lithium carbonate	Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
MME	membrane metalloendopeptidase	Metabolism of Angiotensinogen to Angiotensins Neutrophil degranulation	Candoxatril Omapatrilat N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine Phosphoramidon N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala Daglutril 2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM Thiorphan Sacubitril Candoxatrilat
FCGR2B	Fc fragment of IgG receptor IIb	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	Etanercept Human immunoglobulin G Abciximab Tositumomab Alemtuzumab Antithymocyte immunoglobulin (rabbit) Palivizumab Daclizumab Bevacizumab Sarilumab	Systemic lupus erythematosus
CDK1	cyclin dependent kinase 1	MAPK3 (ERK1) activation E2F-enabled inhibition of pre-replication complex formation Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 Golgi Cisternae Pericentriolar Stack Reorganization Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes APC/C:Cdc20 mediated degradation of Cyclin B Cdc20:Phospho-APC/C mediated degradation of Cyclin A Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of the APC/C Phosphorylation of Emi1 Condensation of Prophase Chromosomes MASTL Facilitates Mitotic Progression Resolution of Sister Chromatid Cohesion Condensation of Prometaphase Chromosomes Regulation of PLK1 Activity at G2/M Transition Activation of NIMA Kinases NEK9, NEK6, NEK7 Initiation of Nuclear Envelope (NE) Reformation Nuclear Pore Complex (NPC) Disassembly Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Depolymerisation of the Nuclear Lamina Anchoring of the basal body to the plasma membrane MAPK6/MAPK4 signaling Ovarian tumor domain proteases TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Regulation of TP53 Degradation Mitotic Prophase G1/S-Specific Transcription Cyclin A/B1/B2 associated events during G2/M transition Cyclin A/B1/B2 associated events during G2/M transition G2/M DNA replication checkpoint Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 Transcriptional regulation by RUNX2	Indirubin-3'-monoxime Olomoucine Hymenialdisine SU9516 Alvocidib Alsterpaullone Seliciclib AT-7519 Fostamatinib
FCGR2A	Fc fragment of IgG receptor IIa	FCGR activation FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis Neutrophil degranulation FCGR3A-mediated IL10 synthesis	Cetuximab Etanercept Human immunoglobulin G Abciximab Alemtuzumab Daclizumab Bevacizumab Catumaxomab Sarilumab	Systemic lupus erythematosus
MAPK3	mitogen-activated protein kinase 3	MAPK3 (ERK1) activation RAF-independent MAPK1/3 activation ISG15 antiviral mechanism Spry regulation of FGF signaling Frs2-mediated activation ERK/MAPK targets ERK/MAPK targets ERKs are inactivated Regulation of actin dynamics for phagocytic cup formation Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Oncogene Induced Senescence FCERI mediated MAPK activation Regulation of HSF1-mediated heat shock response NCAM signaling for neurite out-growth RSK activation Signal transduction by L1 Activation of the AP-1 family of transcription factors Thrombin signalling through proteinase activated receptors (PARs) Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate NADPH Oxidases RAF/MAP kinase cascade MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RNA Polymerase I Promoter Opening Signal attenuation Advanced glycosylation endproduct receptor signaling Gastrin-CREB signalling pathway via PKC and MAPK ESR-mediated signaling RUNX2 regulates osteoblast differentiation Regulation of PTEN gene transcription Regulation of the apoptosome activity Estrogen-dependent nuclear events downstream of ESR-membrane signaling Suppression of apoptosis Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants FCGR3A-mediated phagocytosis Growth hormone receptor signaling	Sulindac Acetylsalicylic acid Minocycline Arsenic trioxide Purvalanol 5-iodotubercidin Seliciclib Cholecystokinin Ulixertinib
BTK	Bruton tyrosine kinase	ER-Phagosome pathway MyD88:MAL(TIRAP) cascade initiated on plasma membrane Regulation of actin dynamics for phagocytic cup formation DAP12 signaling FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization G alpha (q) signalling events G alpha (12/13) signalling events MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) RHO GTPases Activate WASPs and WAVEs G beta:gamma signalling through BTK FCGR3A-mediated phagocytosis Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Dasatinib Inositol 1,3,4,5-Tetrakisphosphate XL418 Ibrutinib Acalabrutinib Fostamatinib Zanubrutinib Abivertinib	Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8 Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
CSF1R	colony stimulating factor 1 receptor	Other interleukin signaling Transcriptional Regulation by VENTX	Imatinib Sunitinib ABT-869 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE Fostamatinib Erdafitinib Pexidartinib	Choriocarcinoma
CD19	CD19 molecule	PIP3 activates AKT signaling Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Constitutive Signaling by Aberrant PI3K in Cancer PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of Complement cascade Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Coltuximab ravtansine Blinatumomab Inebilizumab Tisagenlecleucel Axicabtagene ciloleucel Tafasitamab Brexucabtagene autoleucel	Common variable immunodeficiency (CVID), including the following four diseases: Inducible T Cell costimulator (ICOS) defect; TACI defect; CD19 defect; BAFFR defect
MS4A1	membrane spanning 4-domains A1		Rituximab Ibritumomab tiuxetan Tositumomab Ofatumumab Obinutuzumab Technetium Tc-99m nofetumomab merpentan Ocrelizumab
SYK	spleen associated tyrosine kinase	GPVI-mediated activation cascade GPVI-mediated activation cascade FCGR activation FCGR activation Regulation of actin dynamics for phagocytic cup formation Role of phospholipids in phagocytosis DAP12 signaling Fc epsilon receptor (FCERI) signaling Fc epsilon receptor (FCERI) signaling Role of LAT2/NTAL/LAB on calcium mobilization Role of LAT2/NTAL/LAB on calcium mobilization FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization Integrin signaling CLEC7A (Dectin-1) signaling Dectin-2 family Dectin-2 family Interleukin-2 signaling Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis FLT3 signaling through SRC family kinases Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Staurosporine N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide Tamatinib 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide Ellagic acid Fostamatinib
CSF2RA	colony stimulating factor 2 receptor subunit alpha	Interleukin-3, Interleukin-5 and GM-CSF signaling RAF/MAP kinase cascade Surfactant metabolism Defective CSF2RB causes SMDP5 Defective CSF2RA causes SMDP4 Interleukin receptor SHC signaling	Sargramostim KB002 Regramostim Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal) Clove oil
CSF3R	colony stimulating factor 3 receptor	Other interleukin signaling Transcriptional regulation of granulopoiesis	Pegfilgrastim Filgrastim FavId Lenograstim Lipegfilgrastim
EPOR	erythropoietin receptor	Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS	Darbepoetin alfa Erythropoietin Dibromotyrosine Peginesatide Methoxy polyethylene glycol-epoetin beta	Congenital polycythemia; Familial erythrocytosis (ECYT)

Search Results for: LYN